UNSPSC 51151662: Tiemonium

This classification denotes an antimuscarinic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5Y5LZ9A0KV. European Medicines Agency schedules Tiemonium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15570MIG. The term TIEMONIUM is an International Non-Proprietary Name or INN. As of Q4 2014, TIEMONIUM remains the US FDA Preferred Term for this commodity. Tiemonium bears US NLM identifiers UMLS ID C0771438 and NCI Concept Code C84209. SMILES: C[N+]1(CCOCC1)CCC(C2=CC=CC=C2)(C3=CC=CS3)O.

UNSPSC 51151662 Tiemonium, a Commodity code, represents pharmaceutical products and related health-system support goods procured by state and local public-health and human-services agencies. State and local governments soliciting under this code are acquiring naloxone and drug-deactivation systems for community health initiatives, as well as exploring direct-to-manufacturer pharmacy benefit programs that bypass traditional pharmacy benefit managers and wholesalers. The issuing bodies include county health departments and state health and human services commissions conducting both traditional competitive bidding and exploratory market-intelligence gathering to inform future procurement strategies.

Recent activity shows Seminole County, Florida, in June 2026 issuing IFB 60459723LAS for annual procurement of 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems with quarterly deliveries to the Seminole County Community Health Building in Sanford, using a fixed-fee competitive bidding structure with a two-year initial term and one-year renewal option. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities and market intelligence on direct-to-manufacturer prescription programs that would establish relationships between the state's pharmacy benefit program and pharmaceutical manufacturers outside traditional intermediaries. Geographic activity includes Florida and Texas in the most recent cycle, with the issuing bodies representing both county-level public health operations and state-level pharmacy benefit administration.